Physician profile
Anne E Miller
NPI 1255334637
$5,722.25
in general payments reported to CMS, 2019-2025
24 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,450 · 2020: $35.97 · 2021: $78.17 · 2022: $717 · 2023: $790 · 2024: $1,439 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661 · Travel and Lodging: $682 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,661.21 |
| Travel and Lodging | $682.15 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,844.27 | 2019-2025 | Hydrus Microstent, Rocklatan, Rhopressa |
| Abbvie INC. | $1,385.65 | 2022-2025 | |
| Glaukos Corporation | $460.83 | 2021-2025 | Idosetr, Photrexa Cross-Linking Kit, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Allergan, INC. | $318.61 | 2019-2022 | |
| New World Medical,INC. | $313.72 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $250.63 | 2023-2025 | Acthar |
| Bausch & Lomb Americas INC. | $206.13 | 2024-2025 | Xiidra, Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $152.14 | 2019-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $117.25 | 2019 | |
| Ocular Therapeutix, INC. | $112.82 | 2024-2025 | Dextenza |
| Oyster Point Pharma, INC. | $107.84 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $107.47 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $96.12 | 2023-2024 | Eylea, Eylea Hd |
| Tarsus Pharmaceuticals, INC. | $67.09 | 2024-2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $52.44 | 2023 | Syfovre |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $19.58 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ivantis, INC | $19.21 | 2021 | |
| Biotissue Holdings INC. | $16.46 | 2025 | |
| Dompe US, INC. | $15.88 | 2022 | |
| Alcon Research LLC | $14.50 | 2019 | |
| Lensar, INC. | $12.20 | 2025 | Lensar Laser System |
| Optos, INC. | $12.01 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.